191 related articles for article (PubMed ID: 10999121)
1. Anaemia, iron studies and erythropoietin in patients of chronic renal failure.
Singh NP; Aggarwal L; Singh T; Anuradha S; Kohli R
J Assoc Physicians India; 1999 Mar; 47(3):284-90. PubMed ID: 10999121
[TBL] [Abstract][Full Text] [Related]
2. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients.
Mircescu G; Gârneata L; Capusa C; Ursea N
Nephrol Dial Transplant; 2006 Jan; 21(1):120-4. PubMed ID: 16144853
[TBL] [Abstract][Full Text] [Related]
3. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
[TBL] [Abstract][Full Text] [Related]
4. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
5. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
6. Monitoring the content of reticulocyte hemoglobin (CHr) as the progression of anemia in nondialysis chronic renal failure (CRF) patients.
Tsuchiya K; Saito M; Okano-Sugiyama H; Nihei H; Ando M; Teramura M; Iwamoto YS; Shimada K; Akiba T
Ren Fail; 2005; 27(1):59-65. PubMed ID: 15717636
[TBL] [Abstract][Full Text] [Related]
7. Folic acid deficiency modifies the haematopoietic response to recombinant human erythropoietin in maintenance dialysis patients.
Schiffl H; Lang SM
Nephrol Dial Transplant; 2006 Jan; 21(1):133-7. PubMed ID: 16144854
[TBL] [Abstract][Full Text] [Related]
8. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
Toblli JE; Lombraña A; Duarte P; Di Gennaro F
J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
[TBL] [Abstract][Full Text] [Related]
9. Soluble transferrin receptor is correlated with erythropoietin sensitivity in dialysis patients.
Daschner M; Mehls O; Schaefer F
Clin Nephrol; 1999 Oct; 52(4):246-52. PubMed ID: 10543327
[TBL] [Abstract][Full Text] [Related]
10. [Measuring the content of reticulocyte hemoglobin (CHr) in predialysis chronic renal failure (CRF) patients].
Saito M; Tsuchiya K; Ando M; Akiba T; Nihei H
Nihon Jinzo Gakkai Shi; 2003 Jul; 45(5):430-8. PubMed ID: 14509218
[TBL] [Abstract][Full Text] [Related]
11. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin.
Aggarwal HK; Nand N; Singh S; Singh M; Hemant ; Kaushik G
J Assoc Physicians India; 2003 Feb; 51():170-4. PubMed ID: 12725261
[TBL] [Abstract][Full Text] [Related]
12. The cardiovascular and hemodynamic effects of erythropoietin in chronic renal failure.
Singh NP; Chandrashekhar ; Nair M; Anuradha S; Kohli R; Agarwal SK
J Assoc Physicians India; 2000 Mar; 48(3):301-6. PubMed ID: 11229114
[TBL] [Abstract][Full Text] [Related]
13. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2'-deoxyguanosine levels.
Maruyama Y; Nakayama M; Yoshimura K; Nakano H; Yamamoto H; Yokoyama K; Lindholm B
Nephrol Dial Transplant; 2007 May; 22(5):1407-12. PubMed ID: 17264097
[TBL] [Abstract][Full Text] [Related]
14. [Guidelines for the treatment of anemia in chronic renal failure].
Triolo G;
G Ital Nefrol; 2003; 20 Suppl 24():S61-82. PubMed ID: 14666504
[TBL] [Abstract][Full Text] [Related]
15. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
16. Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, Phase III, randomized, double-blind, placebo-controlled study.
Tsuboi M; Ezaki K; Tobinai K; Ohashi Y; Saijo N
Jpn J Clin Oncol; 2009 Mar; 39(3):163-8. PubMed ID: 19164318
[TBL] [Abstract][Full Text] [Related]
17. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia.
Marsillach J; Martínez-Vea A; Marcas L; Mackness B; Mackness M; Ferré N; Joven J; Camps J
Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):347-9. PubMed ID: 17324148
[TBL] [Abstract][Full Text] [Related]
18. Optimal treatment of renal anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetin.
Hörl WH; Vanrenterghem Y; Canaud B; Mann J; Teatini U; Wanner C; Wikström B
Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii25-32. PubMed ID: 15824127
[TBL] [Abstract][Full Text] [Related]
19. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients.
Taylor JE; Peat N; Porter C; Morgan AG
Nephrol Dial Transplant; 1996 Jun; 11(6):1079-83. PubMed ID: 8671972
[TBL] [Abstract][Full Text] [Related]
20. Efficacy prospective study of different frequencies of Epo administration by i.v. and s.c. routes in renal replacement therapy patients.
Messa P; Nicolini MA; Cesana B; Brezzi B; Zattera T; Magnasco A; Moroni G; Campise M
Nephrol Dial Transplant; 2006 Feb; 21(2):431-6. PubMed ID: 16249199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
